These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1061 related items for PubMed ID: 20195219

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42. A Randomized 2x2 Factorial Clinical Trial of Renal Transplantation: Steroid-Free Maintenance Immunosuppression with Calcineurin Inhibitor Withdrawal after Six Months Associates with Improved Renal Function and Reduced Chronic Histopathology.
    Stevens RB, Foster KW, Miles CD, Kalil AC, Florescu DF, Sandoz JP, Rigley TH, Malik T, Wrenshall LE.
    PLoS One; 2015; 10(10):e0139247. PubMed ID: 26465152
    [Abstract] [Full Text] [Related]

  • 43. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
    Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Bergh CH.
    Transplantation; 2010 Apr 15; 89(7):864-72. PubMed ID: 20061999
    [Abstract] [Full Text] [Related]

  • 44. Better actual 10-year renal transplant outcomes of 80% reduced cyclosporine exposure with sirolimus base therapy compared with full cyclosporine exposure without or with concomittant sirolimus treatment.
    Pliszczynski J, Kahan BD.
    Transplant Proc; 2011 Dec 15; 43(10):3657-68. PubMed ID: 22172822
    [Abstract] [Full Text] [Related]

  • 45. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients.
    Kreis H, Cisterne JM, Land W, Wramner L, Squifflet JP, Abramowicz D, Campistol JM, Morales JM, Grinyo JM, Mourad G, Berthoux FC, Brattström C, Lebranchu Y, Vialtel P.
    Transplantation; 2000 Apr 15; 69(7):1252-60. PubMed ID: 10798738
    [Abstract] [Full Text] [Related]

  • 46. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients.
    Asberg A, Midtvedt K, Line PD, Narverud J, Holdaas H, Jenssen T, Reisaeter AV, Johnsen LF, Fauchald P, Hartmann A.
    Transplantation; 2006 Jul 15; 82(1):62-8. PubMed ID: 16861943
    [Abstract] [Full Text] [Related]

  • 47. Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial.
    Weir MR, Mulgaonkar S, Chan L, Shidban H, Waid TH, Preston D, Kalil RN, Pearson TC.
    Kidney Int; 2011 Apr 15; 79(8):897-907. PubMed ID: 21191361
    [Abstract] [Full Text] [Related]

  • 48. CMV infections after two doses of daclizumab versus thymoglobulin in renal transplant patients receiving mycophenolate mofetil, steroids and delayed cyclosporine A.
    Abou-Ayache R, Büchler M, Lepogamp P, Westeel PF, Le Meur Y, Etienne I, Lobbedez T, Toupance O, Caillard S, Goujon JM, Bergougnoux L, Touchard G.
    Nephrol Dial Transplant; 2008 Jun 15; 23(6):2024-32. PubMed ID: 18199693
    [Abstract] [Full Text] [Related]

  • 49. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study.
    Ekberg H, Bernasconi C, Nöldeke J, Yussim A, Mjörnstedt L, Erken U, Ketteler M, Navrátil P.
    Nephrol Dial Transplant; 2010 Jun 15; 25(6):2004-10. PubMed ID: 20106825
    [Abstract] [Full Text] [Related]

  • 50. Calcineurin inhibitor-free protocols: risks and benefits.
    Barbari AG, Stephan AG, Masri MA.
    Saudi J Kidney Dis Transpl; 2007 Mar 15; 18(1):1-23. PubMed ID: 17237886
    [Abstract] [Full Text] [Related]

  • 51. Eight-year outcomes of 'the Cairo Kidney Centre sequential protocol'.
    Fayad T, William E, Tawfik N, Habashy B, Abou-Youssef HS, Shokry S, Khalil S, Morsy A, Barsoum R.
    Exp Clin Transplant; 2015 Apr 15; 13 Suppl 1():23-9. PubMed ID: 25894123
    [Abstract] [Full Text] [Related]

  • 52. Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial.
    Herlenius G, Felldin M, Nordén G, Olausson M, Bäckman L, Gustafsson B, Friman S.
    Transplant Proc; 2010 Dec 15; 42(10):4441-8. PubMed ID: 21168715
    [Abstract] [Full Text] [Related]

  • 53. Evaluating safety and efficacy of rabbit antithymocyte globulin induction in elderly kidney transplant recipients.
    Khanmoradi K, Knorr JP, Feyssa EL, Parsikia A, Jawa P, Dinh DB, Campos S, Zaki RF, Ortiz JA.
    Exp Clin Transplant; 2013 Jun 15; 11(3):222-8. PubMed ID: 23432665
    [Abstract] [Full Text] [Related]

  • 54. Steroid-free maintenance immunosuppression with rapamune and low-dose neoral in pancreas transplant recipients.
    Rajab A, Pelletier RP, Ferguson RM, Elkhammas EA, Bumgardner GL, Henry ML.
    Transplantation; 2007 Nov 15; 84(9):1131-7. PubMed ID: 17998868
    [Abstract] [Full Text] [Related]

  • 55. Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial.
    Guba M, Pratschke J, Hugo C, Krämer BK, Nohr-Westphal C, Brockmann J, Andrassy J, Reinke P, Pressmar K, Hakenberg O, Fischereder M, Pascher A, Illner WD, Banas B, Jauch KW, SMART-Study Group.
    Transplantation; 2010 Jul 27; 90(2):175-83. PubMed ID: 20463641
    [Abstract] [Full Text] [Related]

  • 56. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial.
    Hazzan M, Labalette M, Copin MC, Glowacki F, Provôt F, Pruv FR, Noël C.
    J Am Soc Nephrol; 2005 Aug 27; 16(8):2509-16. PubMed ID: 15987748
    [Abstract] [Full Text] [Related]

  • 57. Conversion to everolimus in kidney transplant recipients: to believe or not believe?
    Cotovio P, Neves M, Santos L, Macário F, Alves R, Mota A.
    Transplant Proc; 2012 Dec 27; 44(10):2966-70. PubMed ID: 23195007
    [Abstract] [Full Text] [Related]

  • 58. Late calcineurin inhibitor withdrawal prevents progressive left ventricular diastolic dysfunction in renal transplant recipients.
    Mourer JS, Ewe SH, Mallat MJ, Ng AC, Rabelink TJ, Bax JJ, Delgado V, de Fijter JW.
    Transplantation; 2012 Oct 15; 94(7):721-8. PubMed ID: 22955227
    [Abstract] [Full Text] [Related]

  • 59. The Cairo kidney center protocol for rapamycin-based sequential immunosuppression in kidney transplant recipients: 2-year outcomes.
    Barsoum RS, Morsey AA, Iskander IR, Morgan MM, Fayad TM, Atalla NT, Wafik H, Grace RA, Adel N, Khalil SS.
    Exp Clin Transplant; 2007 Dec 15; 5(2):649-57. PubMed ID: 18194116
    [Abstract] [Full Text] [Related]

  • 60. Effect of different immunosuppressive regimens on the evolution of distinct metabolic parameters: evidence from the Symphony study.
    Claes K, Meier-Kriesche HU, Schold JD, Vanrenterghem Y, Halloran PF, Ekberg H.
    Nephrol Dial Transplant; 2012 Feb 15; 27(2):850-7. PubMed ID: 21617197
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 54.